Sign In
Buy ANNX
$5.39
+0.130 (+2.47%)
At Close: Jun 03, 2026
Annexon to Present on the Neuroprotective Effects of ANX007 at the 2025 ARVO Annual Meeting and the Retina World Congress
08:00am, Wednesday, 07'th May 2025
Phase 2 ARCHER Data Support Therapeutic Potential for ANX007 to Preserve Vision in Patients who have Dry Age-related Macular Degeneration (AMD) with Geographic Atrophy (GA) Phase 3 ARCHER II Trial Enr
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Wednesday, 16'th Apr 2025
BRISBANE, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devast
Annexon: With IGOS Study Completion, Pre-BLA Meeting In 1st Half 2025 On Deck
07:12am, Tuesday, 15'th Apr 2025
Annexon achieved primary endpoints in two Phase 3 studies for tanruprubart in treating Guillain-Barre Syndrome, setting the stage for a pre-BLA meeting with the FDA in H1 2025. The company has $312 mi
Oral Presentation Features Phase 3 Data Showing Rapid Recovery and Durable Benefit of Tanruprubart (formerly ANX005) on Clinically Meaningful Measures across Multiple Stages of GBS
Oral Plenary Presentation on Tuesday, April 8 Features Phase 3 Data for ANX005, the First Potential Targeted Therapy for GBS, Showing Rapid and Durable Benefit Across Clinical Measures and Time Points
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Monday, 17'th Mar 2025
BRISBANE, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devast
Annexon Reports Fourth Quarter and Year-End 2024 Financial Results, Portfolio Progress and Key Anticipated Milestones
08:00am, Monday, 03'rd Mar 2025
Robust, Consistent Phase 3 Data and Real-World Evidence Outcomes Support ANX005 as Potential First Targeted Therapy for GBS; Pre-BLA Meeting Targeted for 1H 2025 Ahead of Planned Biologics License App
Annexon Biosciences to Present at the TD Cowen 45th Annual Health Care Conference
04:05pm, Wednesday, 26'th Feb 2025
BRISBANE, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devast
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
08:00am, Tuesday, 18'th Feb 2025
BRISBANE, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devasta
BRISBANE, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devasta
Annexon Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
08:00am, Tuesday, 07'th Jan 2025
BRISBANE, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devasta
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Monday, 16'th Dec 2024
BRISBANE, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devasta
Real-World Evidence Study Strengthens the Body of Evidence Supporting ANX005 for Treatment of GBS ANX005 Phase 3 Population Was Matched 1:1 on Prespecified Criteria with Patients in International GBS
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
04:59pm, Friday, 15'th Nov 2024
BRISBANE, Calif., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devasta
Annexon Reports Third Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones
08:00am, Thursday, 14'th Nov 2024
Topline Real-World Evidence (RWE) Comparability and Outcomes Data for ANX005 in Guillain-Barré Syndrome (GBS) Expected by Year-End 2024; Biologics License Application (BLA) Submission Targeted for Fi
